Single-molecule pulling simulations can discern active from inactive enzyme inhibitors

Area of Science:

• Computational chemistry
• Structural biology
• Drug discovery

Background:

• Ligand-protein interactions are crucial for structure-based drug design.
• Traditional docking and molecular dynamics (MD) simulations have limitations in ranking drug analogues consistently with biological data.
• Plasmodium falciparum beta-hydroxyacyl-ACP dehydratase (PfFabZ) is a unique target for antimalarial drug development.

Purpose of the Study:

• To develop and validate an in silico approach for studying molecular interactions and comparing ligand-analogue binding characteristics.
• To identify novel enzyme inhibitors for PfFabZ by integrating computational predictions with experimental validation.
• To establish a robust drug design strategy based on steered molecular dynamics (SMD) force profiles.

Main Methods:

• Utilized a combination of molecular docking and steered molecular dynamics (SMD) simulations.
• Developed an in silico approach to analyze atomistic interactions and binding affinities.
• Mimicked single-molecule pulling experiments using SMD to generate force profiles for compound discrimination.

Main Results:

• The SMD-derived force profiles successfully distinguished active from inactive compounds for the first time.
• A novel compound was designed based on the computational model, and its activity against PfFabZ was predicted.
• Experimental validation confirmed the computational predictions, demonstrating the approach's robustness.

Conclusions:

• The integrated computational approach, particularly SMD, offers a powerful tool for understanding ligand-protein recognition and guiding drug design.
• This method enhances the ability to predict and rank drug analogues, overcoming limitations of traditional techniques.
• The successful application to PfFabZ highlights its potential for developing new antimalarial therapies and other drug discovery efforts.